<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364807">
  <stage>Registered</stage>
  <submitdate>21/08/2013</submitdate>
  <approvaldate>26/08/2013</approvaldate>
  <actrnumber>ACTRN12613000938707</actrnumber>
  <trial_identification>
    <studytitle>Predicting response to biologics in rheumatoid arthritis</studytitle>
    <scientifictitle>Predicting response to biologics in rheumatoid arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational study. Patients receiving bioloigic therapy for treatment of rheumatoid arthritis will be recruited. Patients will be seen prior to treatment and at 4-6 months after commencing treatment. Disease activity will be assessed using standard measures including swollen joint count, tender joint count, C reactive protein and the composite disease acitivty score 28.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response to biologic as determined by disease activity score</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in inflammatory cytokines measured in the serum</outcome>
      <timepoint>4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in gene expression in peripheral blood cells measured by quantitative polymerase chain reaction</outcome>
      <timepoint>4 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with rheumatoid arthritis as defined by American College of Rheumatology Criteria whom the treating clinician has started biological therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwilling to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>2/09/2013</anticipatedstartdate>
    <actualstartdate>12/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago, Christchurch</primarysponsorname>
    <primarysponsoraddress>P.O.Box 4345
Christchurch 8014</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541, 
Wellesley Street, 
Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The introduction of biological disease modifying anti-rheumatic drugs (bDMARDs) has been a major advance in the treatment of rheumatoid arthritis (RA). When conventional therapy fails, bDMARD therapy can be life changing. bDMARDs specifically target key components in the pathways of inflammation causing RA, such as the pro-inflammatory cytokine tumour necrosis factor-a (TNF). Consequently, knowledge of the inflammatory pathways active in individual patients is required for efficient targeting of bDMARDs. We have established a classification of joint synovial tissues, based on the expression of interleukin (IL) 17-A and CD21L genes, reflecting different inflammatory states. Our objective is to determine if we can predict response to anti-TNF therapy based on this system and concentrations of IL-17-related cytokines. The ability to predict response to treatment will improve outcomes for patients with RA and provide cost savings by ensuring that those patients most likely to respond receive these highly effective but expensive drugs.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Otago Ethics Committee</ethicname>
      <ethicaddress>P.O.Box 56
Dunedin 9054</ethicaddress>
      <ethicapprovaldate>2/08/2013</ethicapprovaldate>
      <hrec>13/040</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch 
P.O.Box 4345
Christchurch 8014</address>
      <phone>+6433640953</phone>
      <fax />
      <email>lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch 
P.O.Box 4345
Christchurch 8014</address>
      <phone>+6433640953</phone>
      <fax />
      <email>lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch 
P.O.Box 4345
Christchurch 8014</address>
      <phone>+6433640953</phone>
      <fax />
      <email>lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>